Investigation of Companies: Halper Sadeh LLC is investigating WideOpenWest, Premier, and Kenvue for potential violations of federal securities laws and breaches of fiduciary duties related to their sales to various investment firms.
Shareholder Rights: Shareholders of the mentioned companies are encouraged to learn about their rights and options regarding the proposed transactions, with the firm offering legal assistance on a contingent fee basis.
Legal Support Offered: The law firm represents investors globally who have experienced securities fraud and corporate misconduct, aiming to recover funds and implement corporate reforms.
Contact Information: Interested shareholders can contact Halper Sadeh LLC for a free consultation regarding their legal rights, with provided contact details for attorneys Daniel Sadeh and Zachary Halper.
Wall Street analysts forecast KVUE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KVUE is 19.42 USD with a low forecast of 17.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
Wall Street analysts forecast KVUE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KVUE is 19.42 USD with a low forecast of 17.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
9 Hold
0 Sell
Moderate Buy
Current: 17.260
Low
17.00
Averages
19.42
High
23.00
Current: 17.260
Low
17.00
Averages
19.42
High
23.00
Argus
John Staszak
Hold
to
Buy
upgrade
$120
Al Analysis
2025-11-13
Reason
Argus
John Staszak
Price Target
$120
Al Analysis
2025-11-13
upgrade
Hold
to
Buy
Reason
As previously reported, Argus analyst John Staszak upgraded Kimberly-Clark (KMB) to Buy from Hold with a $120 price target. The firm notes that the stock has underperformed recently, but the company has delivered a Q3 earnings beat and also announced the acquisition of Kenvue (KVUE) that is expected to close in the second half of next year, the analyst tells investors in a research note.
Barclays
Equal Weight
maintain
$17 -> $18
2025-11-10
Reason
Barclays
Price Target
$17 -> $18
2025-11-10
maintain
Equal Weight
Reason
Barclays raised the firm's price target on Kenvue to $18 from $17 and keeps an Equal Weight rating on the shares following the Q3 report. The company's sales came in below expectations, with low incidence levels and continued destocking, the analyst tells investors in a research note. However, the firm sees "some green shoots" in Kenvue's Skin Health and Beauty segment.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for KVUE
Unlock Now
Morgan Stanley
Equal Weight
downgrade
$144 -> $125
2025-11-04
Reason
Morgan Stanley
Price Target
$144 -> $125
2025-11-04
downgrade
Equal Weight
Reason
Morgan Stanley lowered the firm's price target on Kimberly-Clark (KMB) to $125 from $144 and keeps an Equal Weight rating on the shares after the company announced an agreement to acquire Kenvue (KVUE). The firm understands the pullback in shares given a large degree of execution risk with the deal and uncertainty on Kenvue's portfolio, and the analyst is lowering the firm's target to reflect higher risk from the deal and execution uncertainty, though it sees "the glass as more half full" on Kimberly-Clark's stock after the pullback, the analyst tells investors.
Wells Fargo
Equal Weight
downgrade
$129 -> $110
2025-11-04
Reason
Wells Fargo
Price Target
$129 -> $110
2025-11-04
downgrade
Equal Weight
Reason
Wells Fargo lowered the firm's price target on Kimberly-Clark to (KMB) $110 from $129 and keeps an Equal Weight rating on the shares. The firm notes the company intends to acquire Kenvue (KVUE) in a stock and cash deal valued at $48.7B. Kimberly-Clark's stock reaction was historically negative, reflecting a material change in the investment case, risks associated with Kenvue, and needed execution on big synergy targets.
About KVUE
Kenvue Inc. is a consumer health company. The Company’s differentiated portfolio of brands includes Tylenol, Neutrogena, Listerine, Johnson’s, BAND-AID, Aveeno, Zyrtec, and Nicorette. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee’s, ORSLTM, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women’s health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
